UP TO 5 YEARS OF PROVEN
PSORIASIS CONTROL FROM AN IL-231
5 reasons to make ILUMETRI® your IL-23 of choice for patients with moderate-to-severe psoriasis
for up to 5 years.1
IMPROVED – QUALITY OF LIFE
CONVENIENT
– DOSING SCHEDULE
flat pricing across doses.5
*AEs of special interest also included malignancies, NMSC, injection site reactions and drug-related hypersensitivity reactions.
†When assessed at Week 28, compared with other targeted treatments that are usually assessed between 12 weeks and 16 weeks (such as brodalumab, guselkumab, ixekizumab, infliximab and secukinumab).4
Close to 8 out of 10 responder patients maintained a PASI <3 throughout 5 years of continued treatment1
Absolute PASI <5, <3 and <1 response in patients treated with ILUMETRI® 100 mg until Week 244
Adapted from Thaçi Di, et al. 2021.
PASI 75, PASI 90 and PASI 100 responses are well-maintained throughout 5 years of treatment with ILUMETRI®1
Proportions of ILUMETRI® 100 mg responders achieving PASI 75, PASI 90 and PASI 100 responses from Week 28 through Week 244
Adapted from Thaçi Di, et al. 2020.
Data from patients who achieved at least PASI 75 at Week 28 is shown for Week 52.2
*A DLQI score of 0 or 1 indicates no effect of psoriasis on quality of life. The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life.2
ILUMETRI® DEMONSTRATED A CONSISTENT, FAVOURABLE SAFETY PROFILE confirmed by 5-year data, with low rates of AEs of special interest,* including severe infections, malignancies and MACE1,7
- Severe infection rates were low1
- Candida infections were infrequent1,7
No increased risk or worsening events of IBD1,7
- No exacerbations of pre-existing IBD1,7
- Frequencies and exposure-adjusted rates of malignancies, NMSC and melanoma were low1
-
Frequencies and exposure-adjusted rates
were low1
- Severe infection rates were low1
- Candida infections were infrequent7,8
- No exacerbations of pre-existing IBD8
- Frequencies and exposure-adjusted rates of malignancies, NMSC and melanoma were low1
- Frequencies and exposure-adjusted rates were low1
Dosing frequency may influence adherence and, ultimately, the likelihood of treatment success8
Please refer to approved Summary of Product Characteristics.
*Unopened pre-filled syringe. †After training in proper injection technique, patients may self-inject ILUMETRI®.
ILUMETRI® IS MORE COST EFFECTIVE THAN OTHER BIOLOGICS,4* with flat pricing across doses5
The only biologic where patients can continue treatment for 28 weeks before first efficacy assessment4,9–11
-
If <50% reduction in PASI score after starting treatment with ILUMETRI®, consider stopping
between 12 weeks and 28 weeks4
- Stop ILUMETRI® at Week 28 if the psoriasis has not responded adequately4
- 75% reduction in the PASI score (PASI 75) from starting treatment, or
-
50% reduction in the PASI score (PASI 50) and a
5-point reduction in DLQI from starting treatment
- Disease is severe (total PASI score ≥10 and DLQI >10), and
- The disease has not responded to other systemic treatments, including cyclosporin, methotrexate and phototherapy, or these treatments are contraindicated or not tolerated
- The company provides the drug according to the commercial arrangement
- If <50% reduction in PASI score after starting treatment with ILUMETRI®, consider stopping between 12 weeks and 28 weeks4
- Stop ILUMETRI® at Week 28 if the psoriasis has not responded adequately4
- 75% reduction in the PASI score (PASI 75) from starting treatment, or
- 50% reduction in the PASI score (PASI 50) and a 5-point reduction in DLQI from starting treatment
- Disease is severe (total PASI score ≥10 and DLQI >10), and
- The disease has not responded to other systemic treatments, including cyclosporin, methotrexate and phototherapy, or these treatments are contraindicated or not tolerated
- The company provides the drug according to the commercial arrangement
References
1. Thaçi D, et al. Br J Dermatol 2021. DOI: 10.1111/bjd.19866.
2. Reich K, et al. Lancet 2017;15:276–288.
3. ILUMETRI® Summary of Product Characteristics. Almirall.
4. NICE. Tildrakizumab for treating moderate to severe plaque psoriasis. Available at: https://www.nice.org.uk/guidance/ta575.
5. ILUMETRI® MIMS. Available at: https://www.mims.co.uk/drugs/skin/psoriasis-seborrhoeaactual-hyphenichthyosis/ilumetri.
6. Almirall. Data on file. IE-TIL-1900005.
7. Reich K, et al. Br J Dermatol 2020;182:605–617.
8. Zhang M, et al. J Drugs Dermatol 2017;16:220–226.
9. NICE. Risankizumab for treating moderate to severe plaque psoriasis. Available at: https://www.nice.org.uk/guidance/ta596.
10. NICE. Guselkumab for treating moderate to severe plaque psoriasis. Available at: https://www.nice.org.uk/guidance/ta521.
11. NICE. Ustekinumab for the treatment of adults with moderate to severe psoriasis. Available at: https://www.nice.org.uk/guidance/ta180.
UK-ILU-2100069 June 2021